A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
With
PPD Development, LP
Age
18–50
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, clinical laboratory tests, vital sign measurements, and 12-lead electrocardiogram results.
Body weight greater than or equal to (\>=) 50 kilograms (kg) (110 pounds-mass/Ibs) and body mass index within the range 19 to 30 kg per meter square (inclusive).
Women who have the potential to become pregnant must use a form of highly-effective contraception.
Capable of giving signed informed consent.
You may not be if
History or presence of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, constituting a risk when taking the study intervention, or interfering with the interpretation of data.
Participants with allergy/intolerance to a monoclonal antibody or biologic or participants with a previous history of clinically significant multiple or severe drug allergies/intolerance.
Current evidence or recent history of an infective illness.
A positive pre-study drug/alcohol screen or a history (or suspected history) of alcohol misuse or substance abuse
Clinically significant abnormalities.
Positive test for severe acute respiratory syndrome coronavirus (SARS-CoV-2) at screening.
Recent prior or concurrent clinical study experience.
Clareo Health | A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants
